Clinical Trial Update: Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating prophylactic risedronate in patients with peripheral lung tumors treated with SBRT; study completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neoplasm

Drugs mentioned

• risedronate (risedronate)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Lung Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2023-07-14